New Medicines of 2015
Ninlaro is a prescription drug used to treat patients with multiple myeloma, a form of blood cancer, who have already received at least one prior therapy. Ninlaro belongs to a group of drugs called proteasome inhibitors, which work to block enzymes in cancer cells, stopping their ability to grow and survive. This medication is typically taken orally once weekly. Common side effects include diarrhea, constipation and low blood platelet count. Ninlaro is used along with two other medications to treat multiple myeloma.
Reviewed by:
Review Date:
December 29, 2015Citation:
U.S. Food and Drug Administration, "FDA approves first-of-its-kind product for the treatment of melanoma", 2015 U.S. Food and Drug Administration, "FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa", 2015 U.S. Food and Drug Administration, "FDA approves Ninlaro, new oral medication to treat multiple myeloma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for HIV", 2015 U.S. Food and Drug Administration, "FDA approves Nucala to treat severe asthma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for advanced pancreatic cancer", 2015 U.S. Food and Drug Administration, "FDA approves first treatment for sexual desire disorder", 2015 U.S. Food and Drug Administration, "FDA approves new drug to treat heart failure", 2015 U.S. Food and Drug Administration, "FDA approves Praluent to treat certain patients with high cholesterol", 2015 U.S. Food and Drug Administration, "FDA approves Corlanor to treat heart failure", 2015 All images appear courtesy of Dreamstime
Last Updated:
December 29, 2015